Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M.
PMID: 17440629
Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.

Agomelatine, AGRO-100, AIDSVAX gp120 B/E, alfimeprase, aliskiren fumarate, ALVAC vCP1452, alvocidib hydrochloride, ambrisentan, AME-527, AN-0128, apadenoson, ARRY-142886, asenapine maleate, axitinib, azimilide hydrochloride; Belimumab, bevacizumab, biolimus A9, BiovaxID, bryostatin 1; Cannabidiol, celgosivir, CG-1940/CG-8711, CKD-501, collagen-PVP, CpG-10101, CTL-102, CTL-102/CB-1954; D-4F, darusentan,...

Cite
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(2):153-73
Bayes, M. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(2), 153-73.
Bayes, Miriam. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,2 (2007): 153-73.
Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PMID: 17440629.
Copy Download .nbib Format: NLM
Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18850047
Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95.

(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher;...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008;30(6):459-95
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. July-August 2008. Methods and findings in experimental and clinical pharmacology, 30(6), 459-95.
Tomillero, A, and Moral, M A. "Gateways to clinical trials. July-August 2008." Methods and findings in experimental and clinical pharmacology vol. 30,6 (2008): 459-95.
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047.
Copy Download .nbib Format: NLM
Efficacy and Synergy of Small Molecule Inhibitors Targeting .

Cancers

Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A.
PMID: 34944800
Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181.

Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring

Cite
Bregante J, Schönbichler A, Pölöske D, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246181.
Bregante, J., Schönbichler, A., Pölöske, D., Degenfeld-Schonburg, L., Monzó Contreras, G., Hadzijusufovic, E., de Araujo, E. D., Valent, P., Moriggl, R., & Orlova, A. (2021). Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers, 13(24), . https://doi.org/10.3390/cancers13246181
Bregante, Javier, et al. "Efficacy and Synergy of Small Molecule Inhibitors Targeting ." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246181
Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181. PMID: 34944800.
Copy Download .nbib Format: NLM
Speculative assessment, molecular composition, PDOS, topology exploration (ELF, LOL, RDG), ligand-protein interactions, on 5-bromo-3-nitropyridine-2-carbonitrile.

Heliyon

Arulaabaranam K, Muthu S, Mani G, Ben Geoffrey AS.
PMID: 34095571
Heliyon. 2021 May 21;7(5):e07061. doi: 10.1016/j.heliyon.2021.e07061. eCollection 2021 May.

Computational calculations of 5-bromo-3-nitropyridine-2-carbonitrile (5B3N2C) on molecular structure and on energy are implemented using the 6-311++G(d,p) basis set by DFT/B3LYP method. The UV-Vis spectrum of 5B3N2C was obtained by TD-DFT with chloroform as a solvent. The analysis of molecular...

Cite
Arulaabaranam K, Muthu S, Mani G, et al. Speculative assessment, molecular composition, PDOS, topology exploration (ELF, LOL, RDG), ligand-protein interactions, on 5-bromo-3-nitropyridine-2-carbonitrile. Heliyon. 2021;7(5):e07061doi: 10.1016/j.heliyon.2021.e07061.
Arulaabaranam, K., Muthu, S., Mani, G., & Ben Geoffrey, A. S. (2021). Speculative assessment, molecular composition, PDOS, topology exploration (ELF, LOL, RDG), ligand-protein interactions, on 5-bromo-3-nitropyridine-2-carbonitrile. Heliyon, 7(5), e07061. https://doi.org/10.1016/j.heliyon.2021.e07061
Arulaabaranam, K, et al. "Speculative assessment, molecular composition, PDOS, topology exploration (ELF, LOL, RDG), ligand-protein interactions, on 5-bromo-3-nitropyridine-2-carbonitrile." Heliyon vol. 7,5 (2021): e07061. doi: https://doi.org/10.1016/j.heliyon.2021.e07061
Arulaabaranam K, Muthu S, Mani G, Ben Geoffrey AS. Speculative assessment, molecular composition, PDOS, topology exploration (ELF, LOL, RDG), ligand-protein interactions, on 5-bromo-3-nitropyridine-2-carbonitrile. Heliyon. 2021 May 21;7(5):e07061. doi: 10.1016/j.heliyon.2021.e07061. eCollection 2021 May. PMID: 34095571; PMCID: PMC8165421.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20664824
Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420.

[¹¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[¹⁸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(5):331-88doi: 10.1358/mf.2010.32.5.1520420.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(5), 331-88. https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,5 (2010): 331-88. doi: https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 19088949
Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72.

Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(8):643-72
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(8), 643-72.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,8 (2008): 643-72.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949.
Copy Download .nbib Format: NLM
Efficacy and Synergy of Small Molecule Inhibitors Targeting .

Cancers

Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A.
PMID: 34944800
Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181.

Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring

Cite
Bregante J, Schönbichler A, Pölöske D, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246181.
Bregante, J., Schönbichler, A., Pölöske, D., Degenfeld-Schonburg, L., Monzó Contreras, G., Hadzijusufovic, E., de Araujo, E. D., Valent, P., Moriggl, R., & Orlova, A. (2021). Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers, 13(24), . https://doi.org/10.3390/cancers13246181
Bregante, Javier, et al. "Efficacy and Synergy of Small Molecule Inhibitors Targeting ." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246181
Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181. PMID: 34944800.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 17235418
Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(10):719-40
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(10), 719-40.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,10 (2006): 719-40.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PMID: 17235418.
Copy Download .nbib Format: NLM
KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.

Neuro-oncology advances

Terribas E, Fernández M, Mazuelas H, Fernández-Rodríguez J, Biayna J, Blanco I, Bernal G, Ramos-Oliver I, Thomas C, Guha R, Zhang X, Gel B, Romagosa C, Ferrer M, Lázaro C, Serra E.
PMID: 32642733
Neurooncol Adv. 2020 Jan 04;2:i62-i74. doi: 10.1093/noajnl/vdz061. eCollection 2020 Jul.

BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) constitutes the leading cause of neurofibromatosis type 1-related mortality. MPNSTs contain highly rearranged hyperploid genomes and exhibit a high division rate and aggressiveness. We have studied in vitro whether the mitotic kinesins...

Cite
Terribas E, Fernández M, Mazuelas H, et al. KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. Neurooncol Adv. 2020;2:i62-i74doi: 10.1093/noajnl/vdz061.
Terribas, E., Fernández, M., Mazuelas, H., Fernández-Rodríguez, J., Biayna, J., Blanco, I., Bernal, G., Ramos-Oliver, I., Thomas, C., Guha, R., Zhang, X., Gel, B., Romagosa, C., Ferrer, M., Lázaro, C., & Serra, E. (2020). KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. Neuro-oncology advances, 2i62-i74. https://doi.org/10.1093/noajnl/vdz061
Terribas, Ernest, et al. "KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors." Neuro-oncology advances vol. 2 (2020): i62-i74. doi: https://doi.org/10.1093/noajnl/vdz061
Terribas E, Fernández M, Mazuelas H, Fernández-Rodríguez J, Biayna J, Blanco I, Bernal G, Ramos-Oliver I, Thomas C, Guha R, Zhang X, Gel B, Romagosa C, Ferrer M, Lázaro C, Serra E. KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. Neurooncol Adv. 2020 Jan 04;2:i62-i74. doi: 10.1093/noajnl/vdz061. eCollection 2020 Jul. PMID: 32642733; PMCID: PMC7317059.
Copy Download .nbib Format: NLM
Efficacy and Synergy of Small Molecule Inhibitors Targeting .

Cancers

Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A.
PMID: 34944800
Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181.

Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring

Cite
Bregante J, Schönbichler A, Pölöske D, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246181.
Bregante, J., Schönbichler, A., Pölöske, D., Degenfeld-Schonburg, L., Monzó Contreras, G., Hadzijusufovic, E., de Araujo, E. D., Valent, P., Moriggl, R., & Orlova, A. (2021). Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers, 13(24), . https://doi.org/10.3390/cancers13246181
Bregante, Javier, et al. "Efficacy and Synergy of Small Molecule Inhibitors Targeting ." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246181
Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A. Efficacy and Synergy of Small Molecule Inhibitors Targeting . Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246181. PMID: 34944800; PMCID: PMC8699584.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries